Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 4/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18818374 | 0.97 | HDAC1 (0.54) | HDAC1HDAC2TLR2MDM2MDM4 | |
| SCHEMBL29984428 | 0.97 | HDAC1 (0.54) | HDAC1HDAC2TLR2MDM2MDM4 | |
| SCHEMBL13561434 | 0.88 | HDAC1 (0.53) | HDAC1HDAC2TLR2MDM2MDM4 | |
| SCHEMBL21404824 | 0.87 | MDM2 (0.54) | TLR2MDM2MDM4TP53TNF | |
| SCHEMBL18795317 | 0.87 | MDM2 (0.54) | TLR2MDM2MDM4TP53TNF | |
| SCHEMBL6157217 | 0.84 | HDAC1 (0.61) | HDAC1HDAC2TLR2MDM2 | |
| SCHEMBL13311694 | 0.84 | HDAC1 (0.60) | HDAC1HDAC2TLR2TNF | |
| SCHEMBL29818551 | 0.83 | MDM4 (0.54) | TLR2MDM2MDM4TP53 | |
| SCHEMBL6159625 | 0.83 | HDAC1 (0.61) | HDAC1HDAC2MDM2MDM4TP53 | |
| SCHEMBL6157856 | 0.83 | HDAC1 (0.61) | HDAC1HDAC2MDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030047-B2 | Peptide macrocycles against acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170233437-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233437-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | HDAC1 2188/4885HDAC2 4567/4885TLR2 200/4885 |
| US-10030047-B2 | Peptide macrocycles against acinetobacter baumannii | VIP, ARG1, CX3CR1 | HDAC1 2188/4885HDAC2 4567/4885TLR2 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.